Merck KGaA Says FDA Extends Review of Multiple Sclerosis Pill, Caldribine in Setback for Novartis AG

Bloomberg -- U.S. regulators extended the review period for Merck KGaA’s cladribine multiple sclerosis pill by three months, a setback for the drugmaker in the race with Swiss rival Novartis AG.